IQVIA (NYSE:IQV) Updates FY 2025 Earnings Guidance

IQVIA (NYSE:IQV) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 11.700-12.100 for the period, compared to the consensus earnings per share estimate of 11.880. The company issued revenue guidance of $15.7 billion-$16.1 billion, compared to the consensus revenue estimate of $16.0 billion.

IQVIA Price Performance

IQV traded down $1.90 during trading on Friday, reaching $208.06. The company’s stock had a trading volume of 628,633 shares, compared to its average volume of 1,395,699. The firm has a fifty day simple moving average of $200.53 and a two-hundred day simple moving average of $219.80. The company has a market cap of $37.76 billion, a price-to-earnings ratio of 27.27, a PEG ratio of 2.15 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.17% and a net margin of 9.17%. As a group, analysts anticipate that IQVIA will post 10.18 EPS for the current year.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent analyst reports. Barclays decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday. Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday. Deutsche Bank Aktiengesellschaft cut their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Finally, Bank of America dropped their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.